Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 study ...

Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...

Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001).

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.